Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Patients whose cancers were hormone receptor (HR) negative – that is, their tumor cells did not have proteins that bind to ...

Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for ...

Pfizer’s RIF and severance practices face scrutiny in a Dec. 8 New Jersey filing by a former physician challenging OWBPA ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million ...